Video

Q&A with James List, MD, PhD, from Janssen Research and Development: Diabetic Kidney Disease and Treatments for a Growing Healthcare Problem

Author(s):

Diabetic kidney disease can take various forms and affect patients in different ways. How the disease progresses and what can be done to slow that progression is the focus of many researchers in the field.

Diabetic kidney disease can take various forms and affect patients in different ways. How the disease progresses and what can be done to slow that progression is the focus of many researchers in the field.

James List, MD, PhD, Global Therapeutic Area Head, Cardiovascular and Metabolism at Janssen Research and Development discussed why the condition has become a growing concern and what is being done to address the issue through new medications and therapies.

With two medications moving through the pipeline, patients with diabetic kidney disease may soon get a new treatment to prevent their developing end stage kidney disease.

When new medications are developed there are certain questions that usually come with their introduction to patients. These include the safety profile, how the treatments are delivered, and what they will cost for patients. The answers to those questions can sometimes make the difference in the treatment's utilization and success in reaching its goals.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.